PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 2925053

Progastrin processing during antral G-cell hypersecretion in humans.

S Jensen·K Borch·L Hilsted·J F Rehfeld
View original source ↗Export metadata ↓

Abstract

Using radioimmunoassays specific for essential processing sites of human progastrin in combination with chromatography before and after cleavage with trypsin and carboxypeptidase B, we have examined antral biopsy specimens and serum from 10 hypergastrinemic patients with fundic atrophic gastritis and 7 normal control subjects. Four types of processing were studied: N-terminal proteolysis (at the N-terminus of component I, gastrin 34, and gastrin 17); C-terminal proteolysis (at the C-terminus of the amide donor, glycine93 in preprogastrin); alpha-carboxyamidation (of phenylalanine92); and O-sulfation (of tyrosine87). The results show that progastrin during permanent G-cell hypersecretion is less completely processed with respect to C-terminal proteolysis, alpha-amidation, and tyrosine-sulfation. In contrast, the degree of N-terminal proteolysis is normal. Thus, the processing of progastrin adjacent to the active site of gastrin is more restrictively controlled than N-terminal processing during G-cell hypersecretion associated with pernicious anemia.

Explore related subjects

Carboxypeptidase BCarboxypeptidasesChromatography, GelGastric MucosaGastrinsGastritisGastritis, AtrophicHumansProtein PrecursorsPyloric AntrumRadioimmunoassayTrypsinJournal ArticleResearch Support, Non-U.S. Gov't

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

S Jensen, K Borch, L Hilsted, J F Rehfeld. 1989. Progastrin processing during antral G-cell hypersecretion in humans.. https://doi.org/10.1016/0016-5085(89)91624-7

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

Evaluation of the iCE280 Analyzer as a potential high-throughput tool for formulation development.

The iCE280 Analyzer (iCE280) was evaluated for its potential application as a high-throughput tool to determine pI and separate charge related species using glycosylated, non-glycosylated and pegylated protein therapeutics as models. Resolution was achieved for glycosylated and non-glycosylated molecules, but remained a challenge for pegylated proteins. The sources of charge variants were determined to be the presence of C-terminal lysine residues, sialic acid content, and deamidation. Limited assay performance evaluation demonstrated that the method was linear in the concentration range of 2-333 microg/ml of IgG with linear regression coefficients of 0.984, 0.998, and 0.990 for acidic, main and basic species, respectively. Limit of detection and limit of quantitation were determined to be 3 and 11 microg/ml. The R.S.D. for intra- and inter-day precision as well as reproducibility was determined to be 0.2% or less for all pI values and 1.4% or less for acidic and main peak area distribution; the R.S.D. for basic peak area distribution was 5.7% or less. Robustness testing was performed by deliberately deviating +/-50% of pharmalyte concentration away from the desired condition. This deviation revealed a pI shift of only 0.06 units and resulted in no significant impact on area percent distribution. Utilization of iCE280 Analyzer eliminated the mobilization step associated with traditional capillary isoelectric focusing analysis and increased analytical throughput at least 2-fold.

Carboxypeptidase B↗
PubMed2006

Cathepsin B activates human trypsinogen 1 but not proelastase 2 or procarboxypeptidase B.

BACKGROUND/AIMS: Activation of trypsinogen to trypsin is a crucial step in the development of acute pancreatitis. The cause of this activation is not known although suggested explanations include autoactivation, cathepsin B-mediated activation and activation by mast cell tryptase. The aim of this study was to investigate cathepsin B and tryptase activation of pancreatic zymogens. METHODS: Trypsinogen-1, proelastase, and procarboxypeptidase B were purified from human pancreatic juice. Human cathepsin B and betaI-tryptase are commercial products. Activation and degradation of zymogens were measured by activity towards specific substrates for trypsin and pancreatic elastase, ELISAs for procarboxypeptidase B and its activation peptide, and a radioimmunoassay for the trypsinogen activation peptide. RESULTS: Cathepsin B caused activation of trypsinogen-1 with a trypsin yield of about 30% of that produced by enterokinase. Proelastase and procarboxypeptidase B was not activated by cathepsin B. None of the zymogens were inactivated by cathepsin B. Neither monomeric nor tetrameric tryptase could activate any of the examined zymogens. CONCLUSION: Cathepsin B is a competent activator of trypsinogen-1, although not as efficient as enterokinase. If cathepsin B is to play a role in protease activation in acute pancreatitis, this most probably occurs by activation of trypsinogen.

Carboxypeptidase B↗
PubMed2004

The intrinsic threshold of the fibrinolytic system is modulated by basic carboxypeptidases, but the magnitude of the antifibrinolytic effect of activated thrombin-activable fibrinolysis inhibitor is masked by its instability.

Activated thrombin-activable fibrinolysis inhibitor (TAFIa) is intrinsically unstable, a property that complicates the study of its role in regulating fibrinolysis. To investigate the effect of basic carboxypeptidases on fibrinolysis under conditions of constant carboxypeptidase activity, we employed pancreatic carboxypeptidase B (CPB), a homologous, stable basic carboxypeptidase, as a surrogate for TAFIa. Clots formed from TAFI-depleted plasma or from purified components were supplemented with tissue-type plasminogen activator and either CPB or TAFIa. The clot lysis data indicate that the down-regulation of fibrinolysis mediated by basic carboxypeptidases involves a threshold mechanism. At carboxypeptidase concentrations above the threshold, plasminogen activation is maintained in a fully down-regulated state; experiments in plasma showed that fibrinolysis is essentially halted by saturating concentrations of TAFIa and that fibrinolysis can be prolonged more than 45-fold by a stable carboxypeptidase. The threshold carboxypeptidase concentration was dependent on tissue-type plasminogen activator and antiplasmin concentrations, indicating that the threshold is determined by the steady-state plasmin concentration. Although obvious with CPB, the threshold was masked by the intrinsic instability of TAFIa and became apparent only when the effect of TAFIa was investigated over the picomolar concentration range. Because of the threshold effect and the instability of TAFIa, exponential increases in TAFIa concentration generate linear increases in lysis time. A model relating lysis time to TAFIa concentration, TAFIa half-life, and the threshold concentration of TAFIa is provided. The threshold effect has potentially important implications regarding the role of TAFIa and the regulation of clot lysis in vivo.

Carboxypeptidase B↗